Literature DB >> 9729972

A prospective study on the dying process in terminally ill cancer patients.

T Morita1, T Ichiki, J Tsunoda, S Inoue, S Chihara.   

Abstract

To determine the physical and medical change in the dying process, a prospective study was performed on 100 terminally ill cancer patients. The mean (median) time from the onset of death rattle, respiration with mandibular movement (RMM), cyanosis on extremities, and pulselessness on the radial artery to death was 57 (23) hours, 7.6 (2.5) hours, 5.1 (1.0) hours, and 2.6 (1.0) hours respectively. Death rattle preceded the other three conditions in 74 percent of the subjects, while RMM preceded cyanosis and pulselessness in 63 percent. The ratio of awake-drowsy-comatose patients was 56-44-0 percent one week before death, 26-62-12 percent in the last 24 hours, and 8-42-50 percent in the final six hours. The number of opioid users and average dose increased significantly as death approached, from 42 percent and 49 mg/day (parental morphine equivalent) four weeks before death to 87 percent and 139 mg/day in the final 48 hours. The frequency of extra dosage also increased significantly, from 32 percent (opioid) and 40 percent (non-opioid) one week before death to 68 percent and 66 percent in the last 48 hours, respectively. The change of physical signs and medical intervention when death is impending has a common pathway in spite of large individual variations; thus, understanding this nature can help clinicians to offer better palliative care to terminal cancer patients.

Entities:  

Mesh:

Year:  1998        PMID: 9729972     DOI: 10.1177/104990919801500407

Source DB:  PubMed          Journal:  Am J Hosp Palliat Care        ISSN: 1049-9091            Impact factor:   2.500


  25 in total

1.  Measuring quality of care at the end of life: who? when? where? and how?

Authors:  R W Meyer
Journal:  West J Med       Date:  2000-06

2.  Appropriate time frames for data collection in quality of life research among cancer patients at the end of life.

Authors:  Siew Tzuh Tang; Ruth McCorkle
Journal:  Qual Life Res       Date:  2002-03       Impact factor: 4.147

Review 3.  [Ermergency diagnostics and therapeutic management of acute dyspnea].

Authors:  A Hüfner; C Dodt
Journal:  Med Klin Intensivmed Notfmed       Date:  2015-10       Impact factor: 0.840

Review 4.  [Recommendations for death rattle].

Authors:  T Pastrana; H Reineke-Bracke; F Elsner
Journal:  Schmerz       Date:  2012-09       Impact factor: 1.107

5.  Clinical factors influencing death rattle breathing in palliative care cancer patients : Non-interventional study.

Authors:  Rudolf Likar; Manuela Christine Michenthaler; Romana Traar; Mario Molnar; Stefan Neuwersch
Journal:  Z Gerontol Geriatr       Date:  2016-05-31       Impact factor: 1.281

6.  Clinical signs of impending death in cancer patients.

Authors:  David Hui; Renata dos Santos; Gary Chisholm; Swati Bansal; Thiago Buosi Silva; Kelly Kilgore; Camila Souza Crovador; Xiaoying Yu; Michael D Swartz; Pedro Emilio Perez-Cruz; Raphael de Almeida Leite; Maria Salete de Angelis Nascimento; Suresh Reddy; Fabiola Seriaco; Sriram Yennu; Carlos Eduardo Paiva; Rony Dev; Stacy Hall; Julieta Fajardo; Eduardo Bruera
Journal:  Oncologist       Date:  2014-04-23

7.  How music-inspired weeping can help terminally ill patients.

Authors:  Kay Norton
Journal:  J Med Humanit       Date:  2011-09

Review 8.  The dying patient.

Authors:  J D Cowan
Journal:  Curr Oncol Rep       Date:  2000-07       Impact factor: 5.075

9.  Longitudinal temporal and probabilistic prediction of survival in a cohort of patients with advanced cancer.

Authors:  Pedro E Perez-Cruz; Renata Dos Santos; Thiago Buosi Silva; Camila Souza Crovador; Maria Salete de Angelis Nascimento; Stacy Hall; Julieta Fajardo; Eduardo Bruera; David Hui
Journal:  J Pain Symptom Manage       Date:  2014-04-16       Impact factor: 3.612

Review 10.  Unexpected death in palliative care: what to expect when you are not expecting.

Authors:  David Hui
Journal:  Curr Opin Support Palliat Care       Date:  2015-12       Impact factor: 2.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.